Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia

American Journal of Hematology
Maro OhanianFarhad Ravandi

Abstract

Based on our previous study of the combination of sorafenib with 5-azacytidine (AZA) in relapsed/refractory patients with FLT3 mutated acute myeloid leukemia (AML), we hypothesized that the combination would be efficacious and well tolerated in untreated patients with FLT3 mutated AML who are unsuitable for standard chemotherapy due to advanced age or lack of fitness. Newly diagnosed patients with untreated FLT3 mutated AML who underwent frontline therapy on 2 separate protocols of AZA plus sorafenib were analyzed. The clinical trials were registered at clinicaltrials.gov (NCT02196857 and NCT01254890). Overall, 27 patients with untreated FLT3 mutated AML (median age of 74 years, range, 61-86) were enrolled. The overall response rate was 78% (7 [26%] CR, 12 [44%] CRi/CRp, and 2 [7%] PR). Patients received a median of 3 treatment cycles (1-35). The median duration of CR/CRp/CRi is 14.5 months (1.1-28.7 months). Three (11%) responding patients (1 CR, 2 CRi) proceeded to allogeneic stem cell transplant. The median follow-up for surviving patients was 4.1 months (3.0-17.3 months). The median overall survival for the entire group was 8.3 months, and 9.2 months in the 19 responders. The regimen was well tolerated in elderly patients w...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Jan 6, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Francesco D'AlòMaria Teresa Voso
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hubert ServeWolfgang E Berdel
Feb 11, 2015·Pediatric Blood & Cancer·Katherine TarlockJessica A Pollard
Nov 29, 2016·European Journal of Haematology·Christina RautenbergThomas Schroeder

❮ Previous
Next ❯

Citations

Feb 5, 2019·Current Oncology Reports·Marco Cerrano, Raphael Itzykson
Jun 28, 2019·Blood·Alexander E Perl
Feb 9, 2020·Current Hematologic Malignancy Reports·Bradley D Hunter, Yi-Bin Chen
May 1, 2020·British Journal of Haematology·Avraham FrischYishai Ofran
Apr 21, 2020·Expert Review of Hematology·Xavier ThomasMaël Heiblig
Oct 20, 2018·International Journal of Molecular Sciences·Dilana StaudtMatthew D Dun
Nov 15, 2018·Cancers·Mario LuppiAdriano Venditti
Feb 26, 2019·Therapeutic Advances in Hematology·Nicholas J ShortNaval Daver
Apr 23, 2020·Current Treatment Options in Oncology·Patrick K Reville, Tapan Kadia
Feb 28, 2020·International Journal of Molecular Sciences·Stephen S Y Lam, Anskar Y H Leung
Apr 26, 2019·International Journal of Molecular Sciences·Stephan R BohlFrank G Rücker
Nov 7, 2019·Therapeutic Advances in Hematology·Guillaume Richard-Carpentier, Courtney D DiNardo
Aug 11, 2020·Expert Opinion on Pharmacotherapy·Alejandro Garcia-Horton, Karen Wl Yee
Sep 22, 2020·Minerva medica·Adrián Mosquera OrgueiraClaudio Cerchione
Jan 12, 2021·Frontiers in Oncology·Vanessa E Kennedy, Catherine C Smith
Mar 6, 2021·Critical Reviews in Oncology/hematology·Flavia Cunha VasconcelosRaquel Ciuvalschi Maia
Feb 24, 2021·Blood Cancer Journal·Hagop KantarjianFarhad Ravandi
Mar 21, 2021·Current Treatment Options in Oncology·Kapil Saxena, Marina Konopleva
Apr 13, 2021·Journal of Biomedical Science·Kunal Nepali, Jing-Ping Liou
May 29, 2021·Blood Cancer Journal·Naval DaverFarhad Ravandi
Jun 5, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew H WeiHagop M Kantarjian
Jun 3, 2021·International Journal of Molecular Sciences·Michael LoschiThomas Cluzeau
Aug 24, 2021·Expert Review of Hematology·Claudio CerchioneGiovanni Martinelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.